The bioreactor hums, a stainless-steel vessel where biology becomes medicine. For decades, the only way to know what was happening inside was to pull a sample, walk it to a lab, and wait hours for an offline assay. The team at IRUBIS, a Munich-based startup founded in 2017, decided the pause was the problem. Their answer is a device called Monipa, a mid-infrared (MIR) spectrometer that fits directly into the process line, offering a real-time read on proteins, metabolites, and contaminants as they flow by [irubis.com]. It is a sensor designed for the factory floor.
The Wedge of Real-Time
IRUBIS's core proposition is to replace the offline sample with an inline measurement. In biopharmaceutical manufacturing, maintaining precise conditions is critical. The Monipa system uses a single-use sensor interface that slots directly into bioreactor or filtration lines, taking continuous MIR readings. The accompanying software uses machine learning models to interpret the spectral data, translating light absorption patterns into concentrations of target molecules like proteins, excipients, and nucleic acids [Perplexity Sonar Pro Brief].
The single-use interface eliminates cross-contamination and tedious cleaning validation. The company reports the technology is advancing its GMP readiness [17, 2026]. Furthermore, IRUBIS has demonstrated integrations with established bioprocessing hardware, like the Repligen KrosFlo KR2i tangential flow filtration system [9, 2026].
The Team and the Traction
IRUBIS was founded by Anja Müller, Alexander Geißler, and Lorenz Sykora-Mirle, who serves as CEO [Perplexity Sonar Pro Brief]. The company's investor list includes BioProcess360, High-Tech Gründerfonds, and the European Innovation Council (EIC) Fund [PitchBook], [High-Tech Gründerfonds, Dec 2020], [European Innovation Council (EIC) Fund, 2023]. Total disclosed funding is approximately $3.4 million, anchored by a €2.8 million seed round [PitchBook], [16, 2026].
| Founder | Role |
|---|---|
| Lorenz Sykora-Mirle | Co-Founder & CEO |
| Anja Müller | Co-Founder |
| Alexander Geißler | Co-Founder |
The Competitive Field
IRUBIS operates in a market for bioprocess monitoring crowded with established players and specialized startups.
- The Incumbent Giants. Companies like Repligen and 908 Devices represent the competitive landscape. Repligen is a provider of bioprocessing technologies, offering a wide array of filtration, chromatography, and analytics systems. IRUBIS has begun to integrate with Repligen's ecosystem [9, 2026]. 908 Devices focuses on handheld and desktop mass spectrometry for bioprocess analysis.
- The Spectroscopy Niche. Other startups are also leveraging advanced spectroscopic techniques for bioprocess monitoring. IRUBIS's differentiation rests on its specific focus on mid-infrared spectroscopy for a broad set of molecules in aqueous solutions, combined with its single-use, inline form factor and machine-learning-driven software.
The Risks in the Recipe
IRUBIS faces hurdles inherent to its category. Sales cycles in biopharma are long, often stretching 18 to 24 months for capital equipment. Convincing risk-averse manufacturers to change a validated process requires extensive testing and regulatory comfort. The company's progress toward GMP readiness is a milestone, not a finish line [17, 2026]. Financing is another watchpoint; the approximately $3.4 million in total disclosed funding is modest for scaling hardware manufacturing in the capital-intensive biotech sector [PitchBook].
The Next Twelve Months
The coming year will likely determine whether IRUBIS transitions from a promising tool used by pioneers to a standard piece of kit in development labs. Key milestones to watch include the formal announcement of a GMP-ready product, the disclosure of a marquee customer name, and a subsequent funding round to fuel commercial scaling.